Bladder Cancer - Featured Clinical Trials
The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:
- Combining Chemotherapy and a PARP Inhibitor for Advanced Solid Tumors
(Posted: 11/03/2009) - In this clinical trial, patients who have solid tumors that cannot be removed by surgery or that have spread to other areas of the body will be treated with the PARP inhibitor AZD2281 and chemotherapy drugs cisplatin and gemcitabine.
- Combination Therapy for Invasive Bladder Cancer
(Posted: 02/05/2008) - In this clinical trial, patients with invasive bladder cancer who are not suitable for cystectomy will be treated with the drug paclitaxel and daily radiation therapy. Additionally, patients whose tumors test positive for a protein called HER2 will be treated with the monoclonal antibody trastuzumab (Herceptin).
- Preventing Bladder Cancer Recurrence and Progression
(Posted: 12/07/2004, Updated: 04/26/2007) - In this study, two types of drugs are being evaluated to see whether they are effective in preventing bladder cancer recurrence and progression after surgery in patients with a history of smoking.
- Targeted Combination Therapy for Advanced Solid Tumors
(Posted: 07/19/2005) - In this study, researchers are assessing the safety and combined effectiveness of bevacizumab and a second drug called sorafenib. Both bevacizumab and sorafenib inhibit the formation of blood vessels to tumors and may act synergistically when combined.
- Chemoprevention of Recurrent Bladder Cancer
(Posted: 06/15/2004) - This trial will study the effectiveness of celecoxib (Celebrex®) in preventing the recurrence of superficial bladder cancer.